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Background
A strong inverse relationship between the plasma con-
centration of HDL-C and the incidence of coronary
heart disease is widely accepted. Few interventions have
succeeded to increase plasma HDL levels in HIV-
infected pts. NVP has a favorable lipid profile, and clini-
cal trials have suggested that it could have a differential
effect on plasma HDL-C levels.
Methods
Prospective, single arm, multicenter study. We included
patients on stable antiretroviral therapy with HIV RNA
≤50 copies/mL for at least one year that were switched
to a NVP-containing regimen. Patients receiving lipid
lowering therapy were excluded. HDL-cholesterol and
other lipid parameters at baseline and after 24 weeks of
treatment with NVP are compared.
Results
Among 130 pts included in the study, 119 (91%) could
be evaluated. BL characteristics: median age 44, female
24%, current smokers 53%. Previous AIDS 29%, CD4
count 502/mm
3. Time on ARV therapy 42 months. Pre-
vious therapy: efavirenz 38%, 3 NRTI 12%, PI 50%.
Accompanying nucleosides were tenofovir/emtricitabine
in 69%, and abacavir/lamivudine in 31%.
Table 1 shows the 24-week results of lipid profile.
At 24 week, the proportion of patients with HDL-
C>40 mg/dl were 69.7% (95%CI 60.7-77.8), compared to
52.1% (95%CI 42.8-61.3) before taking NVP (p<0.01).
The Framingham risk score decreased from 7.6 to 6.6
(p<0.05) after switching to NVP.
Conclusions
Switching to NVP-containing regimens in patients on
stable therapy is associated with a significant increase in
HDL-C and decrease in TC/HDL-c, with an overall
improvement in the Framingham score.
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Table 1
Mean S. D. N p
Triglycerides (mg/dl) Previous treatment 213.8 178.3 119
Nevirapine 154.6 95.3 119 <0.05
TC (mg/dl) Previous treatment 203.6 48.0 119
Nevirapine 198.1 40.5 119 0.108
HDL-C (mg/dl) Previous treatment 43.8 14.6 119
Nevirapine 49.3 16.8 119 <0.05
TC/HDL-C Previous treatment 5.1 1.9 119
Nevirapine 4.3 1.3 119 <0.05
LDL (mg/dl) Previous treatment 120.2 38.1 107
Nevirapine 119.2 32.7 107 0.705
VLDL (mg/dl) Previous treatment 35.1 19.4 25
Nevirapine 23.6 12.6 25 <0.05
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